Formation of Threohydrobupropion from Bupropion Is Dependent on 11β-Hydroxysteroid Dehydrogenase 1

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Drug Metabolism And Disposition

• Publication date

  2013-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.113.052936PMID 23804523PMCID PMC3876805
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?

  2013cited by this paper
• Discovery of SAR184841, a potent and long-lasting inhibitor of 11β-hydroxysteroid dehydrogenase type 1, active in a physiopathological animal model of T2D.

  2013influential reference
• Effect of Ketoconazole on the Pharmacokinetics of the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor ABT-384 and Its Two Active Metabolites in Healthy Volunteers: Population Analysis of Data from a Drug-Drug Interaction Study

  2013influential reference
• 11β-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects.

  2013cited by this paper
• Carbonyl reduction of triadimefon by human and rodent 11β-hydroxysteroid dehydrogenase 1.

  2013cited by this paper
• 11β-Hydroxysteroid dehydrogenase blockade prevents age-induced skin structure and function defects.

  2013influential reference
• 11β-HSD1 inhibition reduces atherosclerosis in mice by altering proinflammatory gene expression in the vasculature.

  2013cited by this paper
• Carbonyl reduction of bupropion in human liver

  2012influential reference
• Tissue-specific modulation of mineralocorticoid receptor function by 11β-hydroxysteroid dehydrogenases: an overview.

  2012cited by this paper
• Protein data bank

  2012cited by this paper
• Lack of Significant Metabolic Abnormalities in Mice with Liver-Specific Disruption of 11β-Hydroxysteroid Dehydrogenase Type 1

  2012cited by this paper
• Bupropion versus methylphenidate in the treatment of children with attention‐deficit/hyperactivity disorder: randomized double‐blind study

  2012cited by this paper
• Hepatic reduction of the secondary bile acid 7-oxolithocholic acid is mediated by 11β-hydroxysteroid dehydrogenase 1.

  2011cited by this paper
• Metabolism of bupropion by baboon hepatic and placental microsomes.

  2011cited by this paper
• The glucocorticoid-activating enzyme 11beta-hydroxysteroid dehydrogenase type 1 has broad substrate specificity: Physiological and toxicological considerations.

  2010cited by this paper
• Bupropion metabolism by human placenta.

  2010cited by this paper
• Medium- and short-chain dehydrogenase/reductase gene and protein families

  2008cited by this paper
• 11-Beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors in Type 2 diabetes mellitus and obesity

  2008cited by this paper
• Medium- and short-chain dehydrogenase/reductase gene and protein families

  2008influential reference
• Hexose-6-phosphate Dehydrogenase Modulates 11β-Hydroxysteroid Dehydrogenase Type 1-Dependent Metabolism of 7-keto- and 7β-hydroxy-neurosteroids

  2007cited by this paper
• Readjusting the glucocorticoid balance: an opportunity for modulators of 11beta-hydroxysteroid dehydrogenase type 1 activity?

  2007cited by this paper
• Pharmacokinetics and Pharmacodynamics of Systemically Administered Glucocorticoids

  2005cited by this paper
• Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.

  2005cited by this paper
• 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL.

  2005cited by this paper
• Effect of bupropion on nocturnal urinary free cortisol and its association with antidepressant response.

  2005cited by this paper
• 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice.

  2005cited by this paper
• Comparative enzymology of 11β-hydroxysteroid dehydrogenase type 1 from six species

  2005cited by this paper
• Hormonal responses during prolonged exercise are influenced by a selective DA/NA reuptake inhibitor

  2004cited by this paper
• Human and rodent type 1 11β-hydroxysteroid dehydrogenases are 7β-hydroxycholesterol dehydrogenases involved in oxysterol metabolism

  2004cited by this paper
• The 11-ketosteroid 11-ketodexamethasone is a glucocorticoid receptor agonist.

  2004cited by this paper
• Rapid hepatic metabolism of 7-ketocholesterol by 11beta-hydroxysteroid dehydrogenase type 1: species-specific differences between the rat, human, and hamster enzyme.

  2004cited by this paper
• Appropriate Function of 11β-Hydroxysteroid Dehydrogenase Type 1 in the Endoplasmic Reticulum Lumen Is Dependent on Its N-terminal Region Sharing Similar Topological Determinants with 50-kDa Esterase*

  2004influential reference
• Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.

  2003cited by this paper
• Purification, characterization and NNK carbonyl reductase activities of 11beta-hydroxysteroid dehydrogenase type 1 from human liver: enzyme cooperativity and significance in the detoxification of a tobacco-derived carcinogen.

  2003cited by this paper
• Stereochemical aspects of carbonyl reduction of the original anticancer drug oracin by mouse liver microsomes and purified 11beta-hydroxysteroid dehydrogenase type 1.

  2003cited by this paper
• Improved protein–ligand docking using GOLD

  2003cited by this paper
• Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation

  2003cited by this paper
• Novel enzymological profiles of human 11beta-hydroxysteroid dehydrogenase type 1.

  2001cited by this paper
• Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.

  2000cited by this paper
• The Protein Data Bank

  2000cited by this paper
• CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.

  2000cited by this paper
• Bupropion

  2000cited by this paper
• Bupropion: a review of its use in the management of smoking cessation.

  2000cited by this paper
• Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion.

  1998cited by this paper
• Selective inhibition of human type 1 11β‐hydroxysteroid dehydrogenase by synthetic steroids and xenobiotics

  1998cited by this paper
• Active site directed mutagenesis of 3 beta/17 beta-hydroxysteroid dehydrogenase establishes differential effects on short-chain dehydrogenase/reductase reactions.

  1997influential reference
• 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess.

  1997cited by this paper
• Pharmacokinetics of Bupropion and its Metabolites in Cigarette Smokers versus Nonsmokers

  1997cited by this paper
• 11β-Hydroxysteroid Dehydrogenase and the Syndrome of Apparent Mineralocorticoid Excess

  1997cited by this paper
• Development and validation of a genetic algorithm for flexible docking.

  1997cited by this paper
• Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder.

  1995cited by this paper
• 11 beta-hydroxysteroid dehydrogenase mediates reductive metabolism of xenobiotic carbonyl compounds.

  1994cited by this paper
• Antidepressant profile of bupropion and three metabolites in mice.

  1990cited by this paper
• Bupropion in depression. II. The role of metabolites in clinical outcome.

  1988cited by this paper
• Pharmacological significance of the species differences in bupropion metabolism.

  1987influential reference
• Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose

  1985cited by this paper
• Metabolism and kinetics of bupropion.

  1983cited by this paper

• Inter-individual variability, differential tissue abundance, and sub-cellular localization of human aldo-keto reductases (AKRs) and hydroxy-steroid dehydrogenases (HSDs).

  2025cites this paper
• The strong clinical interaction between bupropion and CYP2D6 is primarily mediated through bupropion metabolites and their stereoisomers: A paradigm for evaluating metabolites in drug-drug interaction risk.

  2025cites this paper
• Pharmacogenetic Influence on Stereoselective Steady-State Disposition of Bupropion

  2024cites this paper
• Quantitative Analysis of mRNA and Protein Expression Levels of Aldo-Keto Reductase and Short-Chain Dehydrogenase/Reductase Isoforms in the Human Intestine

  2023cites this paper
• In vitro methods to assess 11β-hydroxysteroid dehydrogenase type 1 activity.

  2023cites this paper
• Influence of CYP2B6 Pharmacogenetics on Stereoselective Inhibition and Induction of Bupropion Metabolism by Efavirenz in Healthy Volunteers

  2022cites this paper
• Quantitative Evaluation of the Contribution of Each Aldo-Keto Reductase and Short-Chain Dehydrogenase/Reductase Isoform to Reduction Reactions of Compounds Containing a Ketone Group in the Human Liver

  2022influential citation
• Stereoselective Metabolism of Bupropion to Active Metabolites in Cellular Fractions of Human Liver and Intestine

  2022influential citation
• Pregnancy Has No Clinically Significant Effect on the Pharmacokinetics of Bupropion or Its Metabolites

  2021cites this paper
• Non-P450 Drug-Metabolizing Enzymes: Contribution to Drug Disposition, Toxicity, and Development.

  2021cites this paper
• Subtherapeutic bupropion and hydroxybupropion serum concentrations in a patient with CYP2C19*1/*17 genotype suggesting a rapid metabolizer status

  2020cites this paper
• Transport of Bupropion and its Metabolites by the Model CHO and HEK293 Cell Lines.

  2019cites this paper
• Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects

  2019cites this paper
• Comparison of In Vitro Stereoselective Metabolism of Bupropion in Human, Monkey, Rat, and Mouse Liver Microsomes

  2018cites this paper
• Reductive metabolism of tiaprofenic acid by the human liver and recombinant carbonyl reducing enzymes.

  2017cites this paper
• Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers

  2016cites this paper
• Development, validation and application of a comprehensive stereoselective LC/MS-MS assay for bupropion and oxidative, reductive, and glucuronide metabolites in human urine.

  2016cites this paper
• Implications of Kidney Disease on Metabolic Reduction.

  2016cites this paper
• Stereoselective disposition of bupropion and its three major metabolites : 4-hydroxybupropion, erythro-dihydrobupropion, and threo-dihydrobupropion

  2016cites this paper
• Stereoselective Glucuronidation of Bupropion Metabolites In Vitro and In Vivo

  2016cites this paper
• Stereoselective method to quantify bupropion and its three major metabolites, hydroxybupropion, erythro-dihydrobupropion, and threo-dihydrobupropion using HPLC-MS/MS.

  2016influential citation
• Identification of non‐reported bupropion metabolites in human plasma

  2016cites this paper
• Stereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 4′-OH-bupropion in vitro

  2016cites this paper
• Development and validation of a high-throughput stereoselective LC-MS/MS assay for bupropion, hydroxybupropion, erythrohydrobupropion, and threohydrobupropion in human plasma.

  2016cites this paper
• Metabolism of Bupropion by Carbonyl Reductases in Liver and Intestine

  2015cites this paper
• Morphological behaviour and metabolic capacity of cryopreserved human primary hepatocytes cultivated in a perfused multiwell device

  2015cites this paper
• 11β-Hydroxysteroid dehydrogenase 1: Regeneration of active glucocorticoids is only part of the story.

  2015cites this paper
• CHARACTERIZATION OF THE EFFECT OF CHRONIC KIDNEY DISEASE ON HEPATIC DRUG REDUCTION: IN-VITRO AND IN-VIVO STUDIES OF WARFARIN

  2014cites this paper
• Gene Variants in CYP 2 C 19 Are Associated with Altered In Vivo Bupropion Pharmacokinetics but Not Bupropion-Assisted Smoking Cessation Outcomes s

  2014cites this paper
• Gene Variants in CYP2C19 Are Associated with Altered In Vivo Bupropion Pharmacokinetics but Not Bupropion-Assisted Smoking Cessation Outcomes

  2014cites this paper
• Investigation of Drug Metabolism by Non-Cytochrome P450 Enzymes and Its Clinical Relevance

  2014cites this paper
• Carbonyl reduction pathways in drug metabolism

  2014influential citation
• Main Metabolic Pathways of TAK-802, a Novel Drug Candidate for Voiding Dysfunction, in Humans: The Involvement of Carbonyl Reduction by 11β-hydroxysteroid Dehydrogenase 1

  2013cites this paper